Healthcare AI Advisory

Nelson Advisors is a London-based, sector-exclusive Mergers & Acquisitions (M&A) advisory firm that specializes in the Healthcare Technology (HealthTech) market across the UK, Europe, and North America.

A major pillar of their core expertise is advising companies in the high-growth Healthcare AI sector. They operate in the lower-to-middle market, typically dealing with companies that have an Enterprise Value (EV) between $25 million and $250 million.

M&A and Strategic Services

Nelson Advisors utilises a consultative "Build, Buy, Partner, or Sell" framework designed to maximize shareholder value rather than just pushing for a quick transaction. Their core M&A offerings for Healthcare AI and HealthTech firms include: 

Sell-Side Advisory: Guiding AI founders through valuation, market positioning, buyer matching, and deal execution. They have highlighted a growing trend of early-stage (Seed/Series A) HealthTech AI companies utilizing M&A as a primary exit strategy due to tight venture capital markets.

Buy-Side Advisory & Roll-Up Strategies: Assisting strategic buyers and private equity firms in acquiring AI targets. This is highly relevant as hospital CIOs and healthcare payers look to consolidate single-point AI tools into comprehensive enterprise platforms.

Tech Asset Sales & Divestitures: Helping companies monetise proprietary AI algorithms, intellectual property, or non-core software business units.

Strategic Partnerships & Market Entry: Structuring cross-border alliances, commercial channel partnerships, and international expansion strategies (particularly into the UK and European healthcare ecosystems).

Market Positioning & The "AI Premium"
Unlike generalist investment banks, Nelson Advisors is led by former HealthTech founders who have built, scaled, and exited their own companies (e.g., co-founder Lloyd Price successfully exited Zesty). This operational background heavily influences how they evaluate and market Healthcare AI assets, specifically focusing on:

Real AI vs. Wrapper Hype: In their valuation frameworks, the firm explicitly differentiates between defensible, clinically validated AI models and generic "wrappers" built on top of third-party APIs. The highest market multiples (e.g., EV/Revenue multiples of 6.0x to 8.0x+) are reserved for proprietary AI that can demonstrably replace manual human labor in fields like diagnostics or revenue cycle management.

Regulatory Navigation: They provide deep advisory regarding compliance with complex regional frameworks, such as the EU AI Act, which drastically alters the risk profile and valuation of clinical AI tools entering European markets.

Nelson Advisors LLP
 
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
  
[email protected]  

[email protected]